Manuvera 2024 H. medicinalis Antistasin Homolog
Recombinant E. coli–expressed Hirudo medicinalis novel anticoagulant protein, 28 % antistasin-identical, exceeding hirudin in aPTT inhibition — Manuvera 2024.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Recombinant E. coli–expressed Hirudo medicinalis novel anticoagulant protein, 28 % antistasin-identical, exceeding hirudin in aPTT inhibition — Manuvera 2024.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Recombinant antistasin homolog's in vitro coagulation inhibition does NOT establish clinical efficacy. No FDA-approved derivative; pharmacokinetics and immunogenicity not characterized.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis
- Discovered
- 2024 · Manuvera VA et al.
Biological Targets
- → thrombin (direct); Factor Xa (clotting assay only); other coagulation cascade proteases
Key Citations
- Manuvera VA et al. (2024), Biochem Biophys Res Commun · PMID 38241814
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.